Brokers Issue Forecasts for BioMarin Pharmaceutical Inc.’s FY2020 Earnings (BMRN)

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) – Stock analysts at Gabelli raised their FY2020 EPS estimates for BioMarin Pharmaceutical in a research report issued on Wednesday. Gabelli analyst J. He now forecasts that the biotechnology company will post earnings per share of $2.55 for the year, up from their previous estimate of $2.45. Gabelli also issued estimates for BioMarin Pharmaceutical’s FY2021 earnings at $3.30 EPS.

BioMarin Pharmaceutical (NASDAQ:BMRN) last released its quarterly earnings results on Thursday, October 26th. The biotechnology company reported ($0.07) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.13) by $0.06. BioMarin Pharmaceutical had a negative return on equity of 4.60% and a negative net margin of 12.45%. The business had revenue of $334.18 million during the quarter, compared to analyst estimates of $347.38 million. During the same quarter in the previous year, the company posted $0.02 earnings per share. BioMarin Pharmaceutical’s revenue for the quarter was up 19.4% on a year-over-year basis.

Other equities analysts have also issued research reports about the company. Wedbush raised BioMarin Pharmaceutical from a “neutral” rating to an “outperform” rating in a research note on Thursday. BidaskClub raised BioMarin Pharmaceutical from a “strong sell” rating to a “sell” rating in a research note on Saturday. Leerink Swann reaffirmed an “outperform” rating and issued a $142.00 price objective (up previously from $136.00) on shares of BioMarin Pharmaceutical in a research note on Thursday, October 19th. SunTrust Banks set a $115.00 price objective on BioMarin Pharmaceutical and gave the stock a “buy” rating in a research note on Thursday, October 19th. Finally, Piper Jaffray Companies reaffirmed a “buy” rating and issued a $113.00 price objective on shares of BioMarin Pharmaceutical in a research note on Thursday, September 21st. Three equities research analysts have rated the stock with a sell rating, seven have given a hold rating, sixteen have given a buy rating and one has issued a strong buy rating to the company. The stock presently has an average rating of “Buy” and an average target price of $112.35.

Shares of BioMarin Pharmaceutical (NASDAQ BMRN) opened at $93.02 on Friday. BioMarin Pharmaceutical has a fifty-two week low of $80.10 and a fifty-two week high of $100.51. The company has a quick ratio of 3.81, a current ratio of 4.91 and a debt-to-equity ratio of 0.41.

Large investors have recently bought and sold shares of the stock. Global X Management Co. LLC raised its position in BioMarin Pharmaceutical by 16.8% during the second quarter. Global X Management Co. LLC now owns 1,935 shares of the biotechnology company’s stock valued at $176,000 after purchasing an additional 279 shares during the period. Toronto Dominion Bank raised its position in BioMarin Pharmaceutical by 12.9% during the second quarter. Toronto Dominion Bank now owns 2,124 shares of the biotechnology company’s stock valued at $193,000 after purchasing an additional 243 shares during the period. Commerce Bank purchased a new stake in BioMarin Pharmaceutical during the third quarter valued at approximately $209,000. Cambridge Investment Research Advisors Inc. purchased a new stake in BioMarin Pharmaceutical during the second quarter valued at approximately $213,000. Finally, Cigna Investments Inc. New raised its position in BioMarin Pharmaceutical by 1.5% during the second quarter. Cigna Investments Inc. New now owns 2,377 shares of the biotechnology company’s stock valued at $216,000 after purchasing an additional 36 shares during the period. Institutional investors own 99.25% of the company’s stock.

In related news, EVP Robert Baffi sold 18,415 shares of the business’s stock in a transaction dated Thursday, September 28th. The stock was sold at an average price of $92.43, for a total value of $1,702,098.45. Following the sale, the executive vice president now directly owns 129,083 shares in the company, valued at $11,931,141.69. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP George Eric Davis sold 1,200 shares of the business’s stock in a transaction dated Thursday, November 30th. The stock was sold at an average price of $85.64, for a total value of $102,768.00. The disclosure for this sale can be found here. Insiders sold 23,136 shares of company stock worth $2,139,361 over the last quarter. 1.85% of the stock is owned by company insiders.

COPYRIGHT VIOLATION WARNING: This piece of content was published by Sports Perspectives and is owned by of Sports Perspectives. If you are viewing this piece of content on another domain, it was stolen and republished in violation of U.S. & international trademark and copyright legislation. The original version of this piece of content can be accessed at https://sportsperspectives.com/2017/12/17/brokers-issue-forecasts-for-biomarin-pharmaceutical-inc-s-fy2020-earnings-bmrn.html.

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical Inc is a biotechnology company. The Company develops and commercializes pharmaceuticals for various diseases and medical conditions. As of December 31, 2016, the Company’s therapy portfolio consisted of five products, and multiple clinical and pre-clinical product candidates. Its commercial products include Aldurazyme (laronidase) for Mucopolysaccharidosis I (MPS I), Firdapse (amifampridine phosphate) for Lambert Eaton Myasthenic Syndrome (LEMS), Kuvan (sapropterin dihydrochloride) for phenylketonuria (PKU), Naglazyme (galsulfase) for Mucopolysaccharidosis VI (MPS VI) and Vimizim (elosulfase alpha) for Mucopolysaccharidosis IV Type A (MPS IV A).

Earnings History and Estimates for BioMarin Pharmaceutical (NASDAQ:BMRN)

Receive News & Ratings for BioMarin Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMarin Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply